AHK-Cu vs GHK-Cu: Two Copper Peptides Compared

AHK-Cu vs GHK-Cu at a Glance

GHK-Cu and AHK-Cu are both copper(II)-binding tripeptides, and they are remarkably close in structure: they differ at only the first amino-acid residue. GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper (Gly-His-Lys-Cu), while AHK-Cu is alanyl-L-histidyl-L-lysine bound to copper (Ala-His-Lys-Cu). Swapping glycine for alanine adds a single methyl side chain — and that small change is associated with a meaningful shift in the published research focus of each compound.

Both chelate copper(II) through the histidine imidazole and the peptide backbone, and both function as copper-delivery vehicles to cells. The differences emerge in their origin, the breadth of their literature, and what that literature has actually examined.

The headline takeaway: GHK-Cu is the deeply characterized, broadly studied copper carrier, while AHK-Cu is a narrower, more recent synthetic analog whose strongest published evidence centers on the hair follicle. Both are supplied here as Research Use Only laboratory compounds; nothing below is a human dosing or therapeutic claim.

GHK-Cu: The Classic Copper Carrier

GHK-Cu (Copper Tripeptide-1) is a naturally occurring human peptide. It was first isolated from human serum by Pickart & Thaler (Nature New Biology, 1973) as a tripeptide — later identified as Gly-His-Lys — that prolonged the survival of normal liver cells and stimulated growth in neoplastic liver. Its plasma concentration is reported to decline with age, from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60, which is part of why it has been studied so extensively as a regenerative signal.

Mechanistically, GHK-Cu is a broad, pleiotropic gene modulator. The review by Pickart & Margolina (International Journal of Molecular Sciences, 2018) reports that a Broad Institute Connectivity Map (Affymetrix) analysis found GHK alters expression across a large gene set — stimulating 1,569 genes and suppressing 583 genes at a ≥50% change threshold (about 31.2% of the genes assayed; roughly 59% up and 41% down). That same review summarizes documented GHK-Cu actions including stimulation of collagen, elastin and glycosaminoglycan synthesis by dermal fibroblasts, modulation of the MMP/TIMP balance, angiogenesis and nerve outgrowth, anti-inflammatory and antioxidant/DNA-repair effects, and tissue-repair signaling across skin, lung, liver, bone and stomach lining.

GHK-Cu also has controlled human-skin data behind it. Badenhorst et al. (Journal of Aging Science, 2016) reported that GHK-Cu modulated MMP and TIMP expression, increased collagen and elastin production, and improved facial-wrinkle parameters — the kind of extracellular-matrix (ECM) profile that distinguishes GHK-Cu's skin-and-repair orientation from AHK-Cu's hair-follicle focus. For a deeper single-compound treatment, see our GHK-Cu research guide.

AHK-Cu: The Hair-Focused Analog

AHK-Cu (Copper Tripeptide-3) is a fully synthetic analog of GHK-Cu with no established endogenous human role. Structurally it is identical to GHK-Cu except that glycine at position 1 is replaced by alanine, adding one methyl side chain. Its published research is narrower than GHK-Cu's and is concentrated on hair-follicle biology.

The foundational study is Pyo et al. (Archives of Pharmacal Research, 2007). Working at very low concentrations (10^-12 to 10^-9 M), the researchers reported that AHK-Cu:

• stimulated elongation of cultured human hair follicles ex vivo;
• promoted proliferation of dermal papilla cells (DPCs) in vitro and stimulated dermal-fibroblast proliferation;
• elevated VEGF (vascular endothelial growth factor) production;
• decreased TGF-β1 secretion by dermal fibroblasts; and
• reduced apoptosis markers — cleaved caspase-3 and cleaved PARP — at 10^-9 M.

Taken together, that profile (more VEGF, less TGF-β1, less apoptotic signaling) is consistent with promoting or prolonging the anagen (growth) phase of the hair cycle in the model systems studied. One important caveat for any literature description: the dose-response is biphasic — effects appear at very low pico- to nanomolar concentrations, with higher concentrations reported to inhibit rather than promote. Concentration context therefore matters a great deal when interpreting AHK-Cu findings.

Key Differences

For two molecules separated by a single methyl group, the practical differences are larger than the structure suggests:

Origin

GHK-Cu is endogenous — a naturally occurring component of human plasma with a defined age-related decline. AHK-Cu is fully synthetic, with no established endogenous role. That distinction shapes how each is framed in the literature: GHK-Cu as a restorative "native" signal, AHK-Cu as a designed analog.

Research Focus

GHK-Cu is the classic, heavily studied Pickart copper carrier, with a broad skin / ECM / wound-healing and systemic regenerative literature, plus large-scale gene-modulation data. AHK-Cu is narrower: its strongest published evidence is preclinical hair-follicle and dermal-papilla signaling (VEGF up, TGF-β1 down, anti-apoptotic). The single Gly→Ala swap is what appears to shift AHK-Cu's reported activity toward those follicular and angiogenic outcomes.

Evidence Depth

This is the sharpest divide. GHK-Cu carries far more peer-reviewed literature — including the controlled facial-skin study on MMP/TIMP, collagen and elastin — and is the more validated of the two. AHK-Cu rests largely on the single foundational in vitro / ex vivo Pyo 2007 study plus mechanistic extrapolation, with no robust standalone human clinical trials. Where the evidence is thin, it is worth saying so plainly: AHK-Cu's hair findings are credible but preclinical.

How They Compare in Research

The two compounds overlap in their shared theme — copper delivery. Copper(II) is a cofactor for lysyl oxidase (which cross-links collagen and elastin) and for superoxide dismutase (an antioxidant enzyme), so by ferrying copper into cells, both peptides can support extracellular-matrix and antioxidant pathways. Both have been associated with collagen / elastin / GAG-supporting ECM activity, which is why their effects partially overlap in the literature.

The differentiator is breadth versus targeting: GHK-Cu acts as a broad multi-tissue gene modulator, while AHK-Cu's documented activity is concentrated on targeted hair-follicle angiogenic and anagen signaling. In practice, researchers tend to reach for GHK-Cu when modeling skin ECM, wound healing, or broad regenerative gene programs, and for AHK-Cu when the question is specifically about dermal-papilla and follicular signaling. Copper-peptide stacks that pair complementary mechanisms are discussed in our peptide stacks guide.

Laboratory Handling

Both peptides are typically supplied as lyophilized powders and, like other copper(II) complexes, produce a distinctive blue/teal color in solution from copper coordination. General RUO handling norms (not dosing guidance) apply to both: store lyophilized powder cold and protected from light; reconstitute with an appropriate sterile diluent — for example bacteriostatic or sterile water — per protocol, and keep the reconstituted solution refrigerated for short-term use. Because copper(II) complexes are redox-active and can be sensitive to pH, oxidation, light, and chelator-competing buffers, handle them to preserve the intact Cu-peptide complex, and confirm identity and purity by COA (for example HPLC plus mass spec). Our guide to reading a peptide COA walks through how to interpret that data.

Frequently Asked Research Questions

What is the difference between AHK-Cu and GHK-Cu?

They are copper(II)-binding tripeptides that differ at only the first residue: AHK-Cu is Ala-His-Lys-Cu (INCI Copper Tripeptide-3) and GHK-Cu is Gly-His-Lys-Cu (INCI Copper Tripeptide-1). Alanine carries one extra methyl side chain versus glycine. Both act as copper-delivery peptides, but GHK-Cu is the broad, naturally occurring copper carrier while AHK-Cu is a synthetic analog whose published research focuses on the hair follicle.

Is GHK-Cu naturally found in the body?

Yes — GHK-Cu is a naturally occurring human peptide, first isolated from human serum by Pickart & Thaler in 1973. Its reported plasma level declines with age, from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60. AHK-Cu, by contrast, is fully synthetic with no established endogenous human role.

What does the research say AHK-Cu does to hair follicles?

In the foundational in vitro / ex vivo study (Pyo et al., 2007), AHK-Cu at 10^-12 to 10^-9 M was reported to elongate cultured human hair follicles, increase dermal papilla cell proliferation, raise VEGF, lower TGF-β1, and reduce apoptosis markers — a profile consistent with promoting the anagen growth phase in those model systems. The effect is biphasic, appearing at very low concentrations, so these are preclinical findings, not a human outcome.

Which copper peptide has more research behind it?

GHK-Cu, by a wide margin. It has 50+ years of peer-reviewed literature, large-scale gene-modulation data (a review reports 1,569 genes stimulated and 583 suppressed at a ≥50% change threshold), and controlled human-skin data. AHK-Cu rests mainly on one foundational in vitro / ex vivo study and lacks robust standalone human clinical trials.

Why is AHK-Cu sometimes labeled "Copper Tripeptide-1"?

That is a labeling error. "Copper Tripeptide-1" is the correct INCI name for GHK-Cu; AHK-Cu is "Copper Tripeptide-3." Some vendor pages mislabel AHK-Cu with the GHK-Cu INCI name, so verify against the batch COA rather than relying on the marketing name.